Dr. Marty Makary, President Donald Trump's choice to lead the Food and Drug Administration, pointed out the Biden ...

SAN DIEGO, CA - March 12, 2025 ( NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY) today released the following note authored by its CEO, Jim Joyce.

A September 2024 article in the journal Biomedicines reviewing the findings of clinical trials for ivermectin and chloroquine ...

In partnership with Sekisui Diagnostics, the company and its distribution partners have made the test available across the US.

was declined by the U.S. Food and Drug Administration. Existing PEMGARDA EUA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients remains in effect. “This is a sad day ...

after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members." ...

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™(pemivibart) against LP.8.1 Centers for Disease ...

February 18, 2025--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration ... Emergency Use Authorization (EUA) status in May 2020.